RxDoctor Payments Data

Bradley Pittman

Physician Assistant · Cherokee, OKNPI 1164609046

Payments from drug & device makers

$364in general payments, 2019–2025

Across 18 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$130
  • GSK$76
  • Otsuka America Pharmaceutical, Inc.$52
  • AstraZeneca$43
  • Pharmacosmos Therapeutics Inc.$19
  • Lundbeck LLC$18
  • plus $27 from 3 others

What the payments were for

  • Food & beverage$364100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$364 in reported general payments places this provider in the 55th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$2,639
Medicare patients
51
Services billed
371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide51$51,663
OzempicSemaglutide40$39,326
JardianceEmpagliflozin28$30,624
MounjaroTirzepatide20$21,255
FarxigaDapagliflozin Propanediol23$18,875
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,125
RybelsusSemaglutide13$14,527
InvokanaCanagliflozin12$9,234
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,420
Advair HfaFluticasone Propion/Salmeterol15$6,210
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$4,234
SymbicortBudesonide/Formoterol Fumarate14$3,668
Gabapentin137$2,690
Albuterol Sulfate HfaAlbuterol Sulfate72$1,783
Atorvastatin Calcium156$1,755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$43$22,54337 claims
GSKTrelegy Ellipta$76$16,12518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Cherokee

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →